ARS Pharmaceuticals, Inc. — Director's Dealing 2022

Aug 9, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Silverback Therapeutics, Inc. (SBTX)
CIK: 0001671858
Period of Report: 2022-08-05

Reporting Person: Shawver Laura (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-08-05	Common Stock	M	78740	$1.27	Acquired	254242	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-08-05	Stock option (right to buy)	$1.27	M	78740	Disposed	2030-04-28	Common Stock (78740)	Direct

Footnotes

F1: 25% of the shares vested on April 16, 2021 and the remaining shares shall vest in 36 equal monthly installments thereafter.